Neothetics, Inc. (NASDAQ:NEOT) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Tuesday, October 17th.
Shares of Neothetics (NEOT) traded down $0.03 on Tuesday, reaching $1.24. 492,393 shares of the company traded hands, compared to its average volume of 6,142,598. Neothetics has a fifty-two week low of $0.30 and a fifty-two week high of $2.63.
Neothetics (NASDAQ:NEOT) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20).
TRADEMARK VIOLATION NOTICE: “Neothetics, Inc. (NASDAQ:NEOT) Upgraded to “Sell” at ValuEngine” was first reported by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/neothetics-inc-neot-upgraded-to-sell-by-valuengine/1721092.html.
An institutional investor recently bought a new position in Neothetics stock. Virtu KCG Holdings LLC acquired a new position in Neothetics, Inc. (NASDAQ:NEOT) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 278,219 shares of the biotechnology company’s stock, valued at approximately $150,000. Virtu KCG Holdings LLC owned approximately 2.01% of Neothetics as of its most recent filing with the Securities and Exchange Commission. 4.64% of the stock is owned by institutional investors and hedge funds.
Neothetics Company Profile
Neothetics, Inc is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Neothetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neothetics Inc. and related companies with our FREE daily email newsletter.